

# NHL: Follicular and Marginal Zone Lymphoma Pathways

Patient Name: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_ Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_ Stage: \_\_\_\_\_

Line of Therapy: \_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ \_\_Maint ECOG Performance Status: \_\_\_\_\_ ICD-10 Code: \_\_\_\_\_

Biomarkers/Characteristics: (select all that apply)

CD20 status: \_\_Negative \_\_Positive HIV associated lymphoma: \_\_No \_\_Yes Transplant Candidate: \_\_No \_\_Yes

## Gastric MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma | Stage IE or IIE | *H. pylori* Positive\*

\_\_\_Antibiotic therapy† for *H. pylori* eradication

## Splenic Marginal Zone‡ or Gastric MALT Lymphoma | First Line of Therapy (1<sup>st</sup> Line)

\_\_\_Rituximab§ monotherapy

## Follicular (Grade I-IIIa) and Other Marginal Zone Lymphomas | First Line of Therapy (1<sup>st</sup> Line)

\_\_\_BR: Bendamustine (Bendeka, Treanda) and rituximab§

\_\_\_R-CHOP(21): Cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab§

\_\_\_R-CVP: Cyclophosphamide, vincristine (Vincasar), prednisone, and rituximab§

\_\_\_Rituximab§ monotherapy

## Follicular and Other Marginal Zone Lymphomas | First Line of Therapy (1<sup>st</sup> Line) | Additional options for the elderly or infirm

\_\_\_Chlorambucil (Leukeran)

\_\_\_Chlorambucil (Leukeran) and rituximab§

\_\_\_Cyclophosphamide

\_\_\_Cyclophosphamide and rituximab§

## Follicular Lymphoma (Grade III) | First Line of Therapy (1<sup>st</sup> Line)

\_\_\_R-CHOP(21): Cyclophosphamide, doxorubicin (Adriamycin), vincristine (Vincasar), prednisone, and rituximab§

\_\_\_R-CEOP: Cyclophosphamide, etoposide, vincristine (Vincasar), prednisone, and rituximab§

\* Gastric MALT with translocation 11;18 (t11;18) (q21;q21) predicts a lower response rate to anti-*H. pylori* treatment. Radiation therapy or other local intervention may be indicated.

† Only generic antibiotics are considered pathway options for *H. pylori* eradication

‡ Splenectomy is also a recommended option for splenic marginal zone lymphoma (NCCN 2A)

§ Rituximab may be administered as Rituxan or Rituxan Hycela. When Rituxan Hycela is chosen, treatment with SC rituximab (Rituxan Hycela) should only be initiated after patients have received at least one full dose of IV rituximab (Rituxan)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.